Skip to main content
Menu

AlphaLISA SureFire Ultra Human STAT2 / IRF9 Complex Detection Kit, 100 Assay Points

The AlphaLISA™ SureFire® Ultra™ Human STAT2 / IRF9 Complex assay is a sandwich immunoassay for quantitative detection of the STAT2 / IRF9 complex in cellular lysates using Alpha Technology.

Feature Specification
Application Cell Signaling
Protocol Time 2h at RT
Sample Volume 30 µL

The AlphaLISA™ SureFire® Ultra™ Human STAT2 / IRF9 Complex assay is a sandwich immunoassay for quantitative detection of the STAT2 / IRF9 complex in cellular lysates using Alpha Technology.

Product variants
Compare all
Remove all
Add to compare Add to compare
Remove
Unit Size: 100 Assay Points
Part #:
ALSU-CST2IR9-A-HV
List price
USD 737.00
Your price:
Add to compare Add to compare
Remove
Unit Size: 500 Assay Points
Part #:
ALSU-CST2IR9-A500
List price
USD 2,490.00
Your price:
Add to compare Add to compare
Remove
Unit Size: 10,000 Assay Points
Part #:
ALSU-CST2IR9-A10K
List price
USD 14,982.00
Your price:
Add to compare Add to compare
Remove
Unit Size: 50,000 Assay Points
Part #:
ALSU-CST2IR9-A50K
List price
USD 47,624.00
Your price:
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Loading...

Overview

The STAT2/IRF9 complex is a transcriptional regulatory assembly that mediates interferon signaling in contexts where STAT1 availability is limited or absent. Under canonical type I interferon signaling, STAT1, STAT2, and IRF9 assemble into the trimeric ISGF3 complex; however, STAT2 and IRF9 can also form a functional binary complex capable of binding interferon-stimulated response elements (ISREs) and driving expression of a subset of interferon-stimulated genes (ISGs). This STAT2/IRF9 complex provides a STAT1-independent mechanism for sustaining antiviral gene expression, which is particularly relevant in settings of STAT1 deficiency, viral antagonism of STAT1, or prolonged interferon stimulation where STAT1 levels are depleted. The STAT2/IRF9 complex has been shown to induce a distinct but overlapping ISG signature compared to ISGF3, with implications for the specificity and duration of antiviral responses. Detection of the STAT2/IRF9 complex, as distinct from individual STAT2 or IRF9 proteins or the full ISGF3 trimer, enables characterization of alternative interferon signaling states and is relevant to research in antiviral immunity, autoimmune disease, and viral immune evasion strategies.

The AlphaLISA SureFire Ultra Human STAT2 / IRF9 Complex Detection Kit is a sandwich immunoassay for the quantitative detection of STAT2 / IRF9 complex in cellular lysates, using Alpha Technology.

Formats:

  • The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
  • The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
  • The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
  • The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.

AlphaLISA SureFire Ultra kits are compatible with:

  • Cell and tissue lysates
  • Antibody modulators
  • Biotherapeutic antibodies

AlphaLISA SureFire Ultra kits can be used for:

  • Cellular kinase assays
  • Receptor activation studies
  • High-throughput screening for preclinical studies

How it works

AlphaLISA SureFire Ultra protein complex detection assay principle

The AlphaLISA SureFire Ultra complex assay measures cellular protein-protein interactions (PPI) in a biological sample (e.g. cell lysate).

The assay uses two antibodies which recognize Protein 1 and Protein 2, respectively. AlphaLISA assays require two bead types: Acceptor and Donor Beads. Acceptor Beads are coated with a proprietary CaptSure™ agent to specifically immobilize the first assay antibody, labeled with a CaptSure tag. Donor Beads are coated with streptavidin to capture the second antibody, which is biotinylated. In the presence of the protein complex, the two antibodies bring the Donor and Acceptor Beads in close proximity whereby the singlet oxygen transfers energy to excite the Acceptor Bead, allowing for the generation of a luminescent Alpha signal. The amount of light emission is directly proportional to the quantity of PPI present in the sample.

Complex-detection-AlphaLISA SureFire Ultra assay principle

 

AlphaLISA SureFire Ultra complex detection two-plate assay protocol

The two-plate protocol involves culturing and treating the cells in a 96-well plate before lysis, then transferring lysates into a 384-well OptiPlate™ plate before the addition of complex AlphaLISA SureFire Ultra detection reagents. This protocol enables cell viability and confluence to be monitored. In addition, lysates from a single well can be used to measure multiple targets.

AlphaLISA SureFire Ultra complex two-plate assay protocol

AlphaLISA SureFire Ultra protein complex detection one-plate assay protocol

Detection of the protein complex with AlphaLISA SureFire Ultra reagents can be performed in a single plate used for culturing, treatment, and lysis. No washing steps are required. This HTS designed protocol allows for miniaturization while maintaining robust AlphaLISA SureFire Ultra quality.

AlphaLISA SureFire Ultra protein complex detection one-plate assay protocol

Assay validation

Increased STAT2/IRF9 Complex formation in response to interferons

A431 cells were seeded in a 96-well plate (30,000 cells/well) in complete medium and incubated overnight at 37°C, 5% CO2. Cells were treated with increasing concentrations of IFNβ for 24 hours.

After treatment, the cells were lysed with 50 µL or 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). STAT2/IRF9 Complex and Cofilin Total levels were evaluated using AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 6,000 cells for Complex and 200 for Cofilin) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, IFNβ triggered a dose-dependent increase in STAT2/IRF9 Complex formation with no change to Cofilin levels.

Pharmacological validation (activation) of STAT2/IRF9 Complex

THP-1 cells were seeded in a 96-well plate (200,000 cells/well) and treated with 10 ng/mL IFNβ or IFNγ for 24 hours in complete medium at 37°C, 5% CO2.

After treatment, the cells were washed with HBSS and then lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). STAT2/IRF9 Complex levels were evaluated using the AlphaLISA SureFire Ultra assay. For the detection step, 10 µL of cell lysate (approximately 20,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, treatment with type I or type II interferons increased STAT2/IRF9 Complex formation with no change to Cofilin Total (data not shown).

Pharmacological validation (activation) of STAT2/IRF9 Complex

RPMI 8226 cells were seeded in a 96-well plate (200,000 cells/well) and treated with 10 ng/mL IFNβ for 24 hours in complete medium at 37°C, 5% CO2.

After treatment, the cells were washed with HBSS and then lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). STAT2/IRF9 Complex levels were evaluated using the AlphaLISA SureFire Ultra assay. For the detection step, 10 µL of cell lysate (approximately 20,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, treatment with IFNb increased STAT2/IRF9 Complex formation with no change to Cofilin Total (data not shown).

Pharmacological validation (activation) of STAT2/IRF9 Complex

Assay sensitivity

Assay sensitivity - cell lysate

Cell lysate was prepared from A431 cells cultured to confluence in T175 flasks at 37°C, 5% CO2. Cells were treated with IFNβ for 24 hours and then lysed in 2 mL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm).

Lysate was serially diluted in Lysis Buffer and assayed for STAT2/IRF9 Complex levels using the AlphaLISA SureFire Ultra kit. For the detection step, 10 µL of lysate was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at room temperature. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour in the dark. The plate was read on an Envision using standard AlphaLISA settings.

Approximate number of cells/datapoint is indicated on the graph. This assay can detect STAT2/IRF9 Complex in less than 3,000 cells. The dotted line represents assay background.

Assay sensitivity of STAT2/IRF9 Complex assay

Specifications

Application
Cell Signaling
Automation Compatible
Yes
Brand
AlphaLISA SureFire Ultra
Detection Modality
Alpha
Product Group
Kit
Protocol Time
2h at RT
Sample Volume
30 µL
Shipping Conditions
Shipped in Blue Ice
Target
STAT2 / IRF9
Target Class
Phosphoproteins
Target Species
Human
Technology
Alpha
Therapeutic Area
Autoimmunity
Virology
Unit Size
100 Assay Points

Resources

Are you looking for resources, click on the resource type to explore further.

1-1 of 1 Resources
Guide Icon
Guide
AlphaLISA SureFire Ultra: the ultimate guide for successful experiments

The definitive guide for setting up a successful AlphaLISA SureFire Ultra assay

Several biological processes are regulated by...

Loading...

Revvity AI Assistant Beta

Scroll Icon